Considering their reproducibility, inexpen-siveness, and availability, the orthotopical xenografts constitute good preclinical models to test the novel antitumoral approaches involving chemotherapy and radiotherapy; they would also facilitate the identification of effective EGFR-targeted therapies, as well as the exploration of the new target aimed at the elements relevant to GBM invasion. The gene discussed is EGFR; the disease is glioblastoma.